NAMS (NewAmsterdam Pharma Co NV) Other Current Liabilities : $91.03 Mil (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is NewAmsterdam Pharma Co NV Other Current Liabilities?

NewAmsterdam Pharma Co NV's other current liabilities for the quarter that ended in Dec. 2024 was $91.03 Mil.

NewAmsterdam Pharma Co NV's quarterly other current liabilities declined from Jun. 2024 ($23.55 Mil) to Sep. 2024 ($23.09 Mil) but then increased from Sep. 2024 ($23.09 Mil) to Dec. 2024 ($91.03 Mil).

NewAmsterdam Pharma Co NV's annual other current liabilities increased from Dec. 2022 ($6.15 Mil) to Dec. 2023 ($15.96 Mil) and increased from Dec. 2023 ($15.96 Mil) to Dec. 2024 ($91.03 Mil).

NewAmsterdam Pharma Co NV Other Current Liabilities Historical Data

The historical data trend for NewAmsterdam Pharma Co NV's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NewAmsterdam Pharma Co NV Other Current Liabilities Chart

NewAmsterdam Pharma Co NV Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Other Current Liabilities

0.52

6.15

15.96

91.03

NewAmsterdam Pharma Co NV Quarterly Data
	Dec20	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Current Liabilities	Get a 7-Day Free Trial							15.96	33.06	23.55	23.09	91.03

NewAmsterdam Pharma Co NV Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

NewAmsterdam Pharma Co NV Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of NewAmsterdam Pharma Co NV's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

NewAmsterdam Pharma Co NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (NAS:NAMS) » Definitions » Other Current Liabilities

Comparable Companies

Traded in Other Exchanges

KH6:Germany

Address

Gooimeer 2-35, Naarden, NH, NLD, 1411 DC

Website

https://www.newamsterdampharma.com

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.